Legal provisions of COM(2001)480 - Amendment of Council Directive 93/42/EEC, as amended by Directive 2000/70/EC, as regards medical devices incorporating stable derivates of human blood or human plasma

Please note

This page contains a limited version of this dossier in the EU Monitor.

dossier COM(2001)480 - Amendment of Council Directive 93/42/EEC, as amended by Directive 2000/70/EC, as regards medical devices incorporating ...
document COM(2001)480 EN
date December  7, 2001


Contents

Article 1

Article 1(5) of Directive 93/42/EEC is hereby amended as follows:

(a) point (c) shall be replaced by the following: "(c) medicinal products covered by Directive 65/65/EEC, including medicinal products derived from blood as covered by Directive 89/381/EEC;";

(b) point (e) shall be replaced by the following: "(e) human blood, blood products, plasma or blood cells of human origin or to devices which incorporate at the time of placing on the market such blood products, plasma or cells, with the exception of devices referred to in paragraph 4a;".

Article 2 - Implementation, transitional provisions

1. Before 13 December 2001, Member States shall adopt and publish the laws, regulations and administrative provisions necessary to comply with this Directive. They shall immediately inform the Commission thereof.

Member States shall apply these measures with effect from 13 June 2002.

When Member States adopt these measures, they shall contain a reference to this Directive or shall be accompanied by such reference on the occasion of their official publication. The methods of making such reference shall be laid down by Member States.

2. Member States shall communicate to the Commission the text of the main provisions of national law which they adopt in the field governed by this Directive.

3. Member States shall take the necessary action to ensure that the notified bodies which are responsible pursuant to Article 16 of Directive 93/42/EEC for conformity assessment take account of all relevant information regarding the characteristics and performance of devices incorporating stable derivatives of human blood or human plasma, including in particular the results of any pertinent tests and verification already carried out under the pre-existing national law, regulations or administrative provisions in respect of such devices.

4. For a period of five years following the entry into force of this Directive, Member States shall accept the placing on the market of devices incorporating stable derivatives of human blood or human plasma which conform to the rules in force in their territory on the date on which this Directive enters into force. For a further period of two years, the said devices may be put into service.

Article 3

This Directive shall enter into force on the date of its publication in the Official Journal of the European Communities.

Article 4

This Directive is addressed to the Member States.